Press time:2021-03-31From:CR Pharma [ Font:BigMediumSmall]
On March 31, CR Sanjiu and Ryukakusan, a leading Japanese brand for throat drugs, officially entered into a strategic cooperation agreement, pursuant to which CR Sanjiu will be responsible for the marketing and online as well as offline sales of Ryukakusan’s lozenge granule products in China.
Ryukakusan Co., Ltd. has a history of more than 200 years. It is a pharmaceutical company focusing on throat health, and also a well-known family medicine brand in Japan. Products of Ryukakusan have been hailed as called one of the “must-buy products in Japan” on Chinese online media. Ryukakusan Direct has brought a premium experience to consumers.
Given the rapid development of new retail models and the trend of consumption upgrade, a number of excellent Japanese health care brands, such as Ryukakusan, have been recognized by consumers with their brand awareness and the volume of overseas purchases continuing to increase. Therefore, CR Sanjiu and Ryukakusan will seize opportunities in the industry and join forces to develop the throat health market of China and defend the throat health of Chinese consumers. According to the timetable, Ryukakusan Direct will be launched on the Chinese market in the first half of this year, and will be sold online and in offline retail pharmacies.
Those who attended the signing ceremony were: Fujii Ryuta, President of Ryukakusan Co., Ltd.; Nitta Shinichi, Director of the Safety Management Department; Tsuboi Masaki, Director of the Business Promotion Department; Ito Kazuto, Director of the International Business Department; Yuan Jia, Member of the International Business Department; Qiu Huawei, President of CR Sanjiu; Zhou Hui, Vice President of CR Sanjiu; Yu Xiang, Deputy General Manager of the OTC Division and General Health Division; Bai Jieming, Deputy General Manager of the Investment Development Department; Wang Haowei, Assistant General Manager of the Digital Center and Director of Category the Marketing Department.
